Hypertonic bladder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hypertonic bladder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Mirabegron for Children Aged 6 Months to Under 3 Years with Neurogenic Detrusor Overactivity https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mirabegron-for-children-aged-6-months-to-under-3-years-with-neurogenic-detrusor-overactivity/ Wed, 29 Apr 2026 14:25:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mirabegron-for-children-aged-6-months-to-under-3-years-with-neurogenic-detrusor-overactivity/ This clinical trial is focused on studying a condition known as Neurogenic Detrusor Overactivity (NDO), which is a type of overactive bladder caused by nerve problems. The study is specifically for children aged 6 months to less than 3 years who have this condition. The treatment being tested is a medication called Mirabegron, which is given as a prolonged-release oral suspension. This means the medicine is in liquid form and is designed to release slowly in the body over time.

The purpose of the study is to evaluate how effective and safe Mirabegron is for treating symptoms of an overactive bladder in young children with a neurological cause. The study will also look at how long the medication stays in the body. Participants will receive the medication in gradually increasing doses, followed by a period where they receive a fixed dose. The study will last for up to 52 weeks, during which the children will be monitored for any changes in their condition and any side effects they might experience.

Throughout the study, various tests and observations will be conducted to assess the medication’s impact. These include checking bladder function, monitoring for any leakage episodes, and evaluating the overall acceptability of the treatment. The study will also involve regular health checks, such as vital signs and laboratory tests, to ensure the safety of the participants. The results will help determine if Mirabegron is a suitable treatment option for young children with Neurogenic Detrusor Overactivity.

]]> Study on Overactive Bladder Treatment for Women Using Clostridium Botulinum Neurotoxin Type A and Vibe System https://clinicaltrials.eu/trial/study-on-overactive-bladder-treatment-for-women-using-clostridium-botulinum-neurotoxin-type-a-and-vibe-system/ Wed, 29 Apr 2026 14:24:41 +0000 https://clinicaltrials.eu/trial/study-on-overactive-bladder-treatment-for-women-using-clostridium-botulinum-neurotoxin-type-a-and-vibe-system/ This clinical trial is focused on studying the treatment of overactive bladder (OAB) in women. Overactive bladder is a condition characterized by a sudden, strong need to urinate, which can lead to involuntary leakage of urine. The treatment being tested in this study is called Xeomin, which contains a substance known as Clostridium botulinum neurotoxin type A. This substance is commonly used to relax muscles and is being explored for its potential to help manage symptoms of overactive bladder.

The study aims to assess the safety and initial effectiveness of a new method of administering Xeomin using the Vibe System. The Vibe System is a special device designed to deliver the medication directly to the bladder wall without the use of needles, which may reduce discomfort compared to traditional injections. Participants in the study will receive either Xeomin or a placebo, and the treatment will be administered using the Vibe System. The study will gather feedback from both patients and doctors to evaluate the ease of use and satisfaction with the treatment method.

Throughout the study, participants will be monitored for any side effects and changes in their symptoms. The study will last for a period of several weeks, during which participants will be asked to keep a diary of their urinary symptoms and attend follow-up visits to assess the treatment’s impact. The goal is to determine if this new approach can provide a safe and effective option for managing overactive bladder symptoms in women.

]]>